Table 3.
Summary table of the meta-analysis(continue).
| Tumour grade I/II(III/IV) | Study quality points | CRP detection method | Survival analysis | Hazard ratios | Method to determine 'high' CRP cut-off level | Number of patients with high CRP | summary results |
|---|---|---|---|---|---|---|---|
| 105(32) | 7 | latex photometric immunoassay, turbidimetric immunoassay | OS | Reported in text | ≥10 mg/L | 22 | positive |
| 25(10) | 7 | ELISA | OS | Reported in text | ≥3 mg/L | 47 | positive |
| 26(30) | 5 | immunoturbidimetric assay | OS | Reported in text | ≥10 mg/L | 12 | positive |
| 68(143) | 6 | NR | OS | Estimated | ≥10 mg/L | 43 | Indeterminate |
| 355(24) | 4 | NR | OS | Estimated | >10 mg/L | 32 | positive |
| NR | 4 | turbidimetric immunoassay | OS | Estimated | 75th percentile (≥12 mg/L) |
10 | Indeterminate |
| NR | 5 | latex immunoturbidimetric assay | OS | Estimated | median (>3 mg/L) | 57 | positive |
| NR | 7 | turbidimetric immunoassay | OS | Reported in text | ≥10 mg/L | 27 | positive |
| 341(58) | 7 | NR | OS | Reported in text | ROC curve(≥10 mg/L) | 246 | positive |
| NR | 7 | NR | OS | Reported in text | ROC curve(≥10 mg/L) | 43 | positive |
| 10(11) | 7 | latex photometric immunoassay, turbidimetric immunoassay | OS | Reported in text | ≥10 mg/L | 27 | positive |
| 105(32) | 7 | latex photometric immunoassay, turbidimetric immunoassay | RFS | Reported in text | ≥10 mg/L | 22 | positive |
| 68(143) | 6 | NR | RFS | Estimated | ≥10 mg/L | 43 | Indeterminate |
| NR | 7 | turbidimetric immunoassay | RFS | Reported in text | ≥10 mg/L | 27 | positive |
M, male; F, female; NR, not reported. a, “Sieghart et al A” here means the data in this row from Sieghart et al training cohort, “Sieghart et al B” means the data in this row from Sieghart et al validation cohort; b, the cutoff for multiple primary tumors was 3 in each cohort. Treatment describes whether the patients received surgical resection (S), liver transplantation (LT) or transarterial chemoembolisation(TACE) of HCC. NS, non-surgical therapy. Multiple therapy, including surgical resection and non-surgical therapy. Tumor vascular invasion was defined as presence of either macro- or microscopic vascular invasion(including portal vein invasion,hepatic vein invasion, etc.). Tumor grade was described using the Edmondson-Steiner grading system, studies were grouped as well/moderate (I/II) or poor (III/IV) degrees of differentiation. Study quality is listed using the results of the Newcastle -Ottawa quality assessment scale (Table 1). OS, overall survival; RFS, recurrence-free survival; ROC, receiver operating characteristics.